OXFORD BIOMEDICA
LIVE

Serial Number

87488957

Owner

Oxford BioMedica (UK) Limited

Attorney

Roberta S. Bren

Filing Date

Jun 14, 2017

Add to watchlist:

No watchlists yet
View on USPTO

OXFORD BIOMEDICA Trademark

Serial Number: 87488957 • Registration: 5451207

OXFORD BIOMEDICA is a trademark filed by Oxford BioMedica (UK) Limited on June 14, 2017. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Oxford BioMedica (UK) Limited (3 trademarks)

Transport Way
Oxford OX4 6LT , GB

Entity Type: 99

Trademark Details

Filing Date

June 14, 2017

Registration Date

April 24, 2018

Published for Opposition

November 7, 2017

Goods & Services

[ Clinical medical reagents for use in gene therapy; pharmaceutical preparations for use in gene therapy; therapeutic compositions containing retroviral vector preparations and/or nucleic acid suitable for gene therapy; retroviral vector preparations for use in gene therapy; pharmaceutical preparations containing a retroviral vector delivering genes to cells for use in the treatment of viral and bacterial infections, cancer, HIV and AIDS, neurodegenerative diseases, diseases of the eye, leukemia and bodily conditions associated with impaired immunosystems; Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals; small molecules, vaccines, biologics, enzymes and enzyme preparations all for medical treatment purposes; pharmaceuticals for medical purposes for the delivery of genes to cells; viral, retroviral and non-viral vectors, all for medical purposes in gene therapy; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes; pre-filled vials for medical purposes and for pharmaceutical and biochemical preparations, for use in gene therapy and for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders ]

[ Chemical compositions containing nucleic acids for use in the manufacture of pharmaceuticals and retroviral vector preparations; Chemicals for use in industry and science; enzymes for scientific and research purposes; biochemicals, namely, precursors for in vitro genetic engineering use; polypeptides for in vitro research use, monoclonal antibodies for in vitro scientific or research use; chemicals for use in the purification of proteins for in vitro use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; micro-organisms for laboratory and scientific research use, viruses for laboratory and scientific research use, cell cultures for laboratory and scientific research use, plasmids and cultures of micro-organisms for laboratory and scientific research use, nucleic acid sequences for laboratory and scientific research use, cloning vehicles in the nature of plasmids, microbes and chemical reagents for DNA cloning for laboratory and scientific research use, chemicals for laboratory, scientific and biotechnology research and development and recombinant nucleic acid variations thereof for laboratory and scientific research use, namely, in vitro and in vivo use ]

[ Medical services; ] advisory services relating to vaccination regimes; advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders and contraceptives

Scientific, pharmaceutical and medical research and development; genetic engineering services, biotechnology services, namely, research and development for new products in the field of biotechnology, advisory services relating to gene therapy products and clinical trials, conducting clinical trials

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Feb 25, 2025 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Feb 25, 2025 C15P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Feb 24, 2025 APRE
TEAS SECTION 8 & 15 RECEIVED
Oct 17, 2024 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Apr 24, 2023 REM1
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jun 8, 2018 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jun 8, 2018 COAR
REGISTERED-PRINCIPAL REGISTER
Apr 24, 2018 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Mar 20, 2018 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 20, 2018 AITU
NOTICE OF ALLOWANCE CANCELLED
Mar 6, 2018 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Mar 6, 2018 D1BR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 2, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 7, 2017 NPUB
PUBLISHED FOR OPPOSITION
Nov 7, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 18, 2017 NONP
ASSIGNED TO LIE
Oct 1, 2017 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 18, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 18, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 18, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 18, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 18, 2017 CNEA
ASSIGNED TO EXAMINER
Sep 13, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 21, 2017 NWOS
NEW APPLICATION ENTERED
Jun 17, 2017 NWAP